Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 8/20 | 0.35 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925125 | 0.72 | CYP3A4 (0.46) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL1944948 | 0.72 | CYP3A4 (0.46) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL10855053 | 0.72 | CYP3A4 (0.50) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL31268547 | 0.69 | CYP3A4 (0.61) | CYP3A4CYP2B6POLBB3GNT2HTT | |
| SCHEMBL6589202 | 0.68 | ALDH1A1 (0.46) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL16364392 | 0.65 | CYP3A4 (0.76) | CYP3A4CYP2B6POLBPGRHTT | |
| SCHEMBL13872418 | 0.65 | SMN1; SMN2 (0.61) | CYP3A4POLBKDM4EALDH1A1GAA | |
| SCHEMBL31268541 | 0.64 | CYP3A4 (0.43) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL1833932 | 0.62 | POLB (0.47) | CYP3A4CYP2B6POLBPGRKDM4E | |
| SCHEMBL11681796 | 0.62 | POLB (0.47) | CYP3A4CYP2B6POLBPGRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196933-A1 | MEXILETINE PRODRUGS | FRANKLIN RICHARD (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120165520-A1 | PROCESS FOR THE SYNTHESIS OF PRODRUGS OF OPIOIDS | SHIRE LLC | 2012-06-28 | — | — | US | disclosed |
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | JOSTENS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196933-A1 | MEXILETINE PRODRUGS | SLC16A1, MTPN, SLC16A3 | CYP3A4 180/4885CYP2B6 239/4885POLB 1972/4885 |
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | MEP1A, MEP1B, CTSZ | CYP3A4 15/4885CYP2B6 85/4885POLB 4315/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | CYP3A4 16/4885CYP2B6 13/4885POLB 3874/4885 |
| US-20120165520-A1 | PROCESS FOR THE SYNTHESIS OF PRODRUGS OF OPIOIDS | OPRM1, OPRK1, OPRD1 | CYP3A4 34/4885CYP2B6 5/4885POLB 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.